|  |
| --- |
| **Supplementary Table 1. Monitoring of clinical variables in 124 COVID-19 patients**  |
| **Variable** | **Normal range** | **COVID-19 patients without malignancy (n=124)** |
|
| **PLT (×109/L)** — mean±sd (range) | 125-350 | 192.4±79.9 (54-525) |
|
| Increased — no. (%) | 　 | 3 (2.4%) |
| Decreased — no. (%) | 　 | 25 (20.2%) |
| **Lymphocyte (×109/L)**— mean±sd (range) | 1.1-3.2 | 0.91±0.48 (0.18-2.4) |
|
| Increased — no. (%) |  | 0 |
| Decreased — no. (%) |  | 90 (72.6%) |
| **MPV (fL)**  — mean±sd (range) | 6-12 | 9.1±1.3 (6.6-12.3) |
|
| Increased — no. (%) | 　 | 1 (0.8%) |
| Decreased — no. (%) | 　 | 0 |
| **PT (S)**  — mean±sd (range) | 9.4-12.5 | 13.0±1.4 (8.6-17.8) |
|
| Increased — no. (%) |  | 77 (62.1%) |
| Decreased — no. (%) |  | 1 (0.8%) |
| **APTT (S)**  — mean±sd (range) | 25.1-36.5 | 30.3±3.2 (22.4-38.1) |
|
| Increased — no. (%) | 　 | 2 (1.6%) |
| Decreased — no. (%) | 　 | 9 (7.3%) |
| **FIB (mg/dL)**  — mean±sd (range) | 238-498 | 429.8±88.7 (203-750) |
|
| Increased — no. (%) |  | 27 (21.8%) |
| Decreased — no. (%) |  | 2 (1.6%) |
| **D-dimer (μg/L)**  — mean±sd (range) | 0-500 | 1168.6±3652.7 (35-26315) |
|
| Increased — no. (%) | 　 | 26 (21.0%) |
| **CRP (mg/L)**  — mean±sd (range) | 0-10 | 46.0±51.4 (0.4-290.1) |
|
| Increased — no. (%) | 　 | 80 (64.5%) |
| **PCT (ng/mL)**  — mean±sd (range) | < 0.05 | NA (<0.05-0.94) |
|
| Increased — no. (%) | 　 | 38 (30.6%) |
| **IL-6 (pg/mL)**  — mean±sd (range) | 0-7 | 48.3±66.5 (2.03-522.2) |
|
| Increased — no. (%) | 　 | 79 (63.7%) |